Invesco
SMMT icon

Invesco’s Summit Therapeutics SMMT Stock Holding History

Invesco’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07M Sell
416,847
-109,256
-21% -$1.94M ﹤0.01% 2144
2026
Q1 		$9.97M Buy
526,103
+64,802
+14% +$1.05M ﹤0.01% 1832
2025
Q4 		$8.07M Buy
461,301
+35,226
+8% +$663K ﹤0.01% 1991
2025
Q3 		$8.8M Buy
426,075
+2,048
+0.5% +$49.7K ﹤0.01% 1900
2025
Q2 		$9.02M Buy
424,027
+34,322
+9% +$783K ﹤0.01% 1840
2025
Q1 		$7.52M Sell
389,705
-9,345
-2% -$187K ﹤0.01% 1949
2024
Q4 		$7.12M Buy
399,050
+324,555
+436% +$6.29M ﹤0.01% 2055
2024
Q3 		$1.63M Buy
74,495
+2,818
+4% +$39.4K ﹤0.01% 2693
2024
Q2 		$559K Sell
71,677
-3,800
-5% -$20.5K ﹤0.01% 3231
2024
Q1 		$312K Buy
75,477
+5,448
+8% +$21.7K ﹤0.01% 3512
2023
Q4 		$183K Sell
70,029
-5,570
-7% -$11.5K ﹤0.01% 3585
2023
Q3 		$141K Buy
75,599
+531
+0.7% +$1.01K ﹤0.01% 3672
2023
Q2 		$188K Buy
75,068
+62,084
+478% +$113K ﹤0.01% 3628
2023
Q1 		$22.7K Buy
+12,984
New +$35.4K ﹤0.01% 3809
2022
Q2 		– Sell
-11,273
Closed -$28K – 4132
2022
Q1 		$28K Buy
11,273
+584
+5% +$1.47K ﹤0.01% 3970
2021
Q4 		$28K Sell
10,689
-8,478
-44% -$40.8K ﹤0.01% 4014
2021
Q3 		$96K Buy
19,167
+3,028
+19% +$21.7K ﹤0.01% 3947
2021
Q2 		$120K Buy
+16,139
New +$106K ﹤0.01% 3873

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco's SMMT Position: Q2 2026 in Review

Invesco reduced its Summit Therapeutics (SMMT) stake by 21% in Q2 2026, selling an estimated $1.94M and leaving 416,847 shares worth $6.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

Invesco first reported a position in SMMT in Q2 2021 and has held it in 18 quarters since. The position peaked at $9.97M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Invesco held 416,847 shares of Summit Therapeutics worth $6.07M as of Q2 2026.
  • Invesco sold 109,256 Summit Therapeutics shares in Q2 2026, an estimated $1.94M.
  • Summit Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2144 holding.
  • Invesco first reported a position in Summit Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Invesco's Summit Therapeutics position peaked at $9.97M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.